An update on intracerebral stem cell grafts

Elliot G. Neal, M. Grant Liska, Trenton Lippert, Roger Lin, Melissa Gonzalez, Eleonora Russo, Kaya Xu, Xunming Ji, Fernando Vale Diaz, Harry Van Loveren, Cesario V. Borlongan

Research output: Contribution to journalReview article

Abstract

Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for clinically feasible stem cell-based treatments. Expert commentary: Intracerebral administration, compared to peripheral delivery, is more invasive and carries the risk of open brain surgery. However, direct cell implantation bypasses the blood–brain barrier and reduces the first-pass effect, effectively increasing the therapeutic cell deposition at its intended site of action. These benefits must be weighed with the risk of graft-versus-host immune response. Rigorous clinical trials are underway to assess the safety and efficacy of intracerebral transplants, and if successful will lead to widely available stem cell therapies for neurologic diseases in the coming years.

Original languageEnglish (US)
Pages (from-to)557-572
Number of pages16
JournalExpert Review of Neurotherapeutics
Volume18
Issue number7
DOIs
StatePublished - Jul 3 2018

Fingerprint

Stem Cells
Cell- and Tissue-Based Therapy
Transplants
Nervous System Diseases
Safety
Central Nervous System Diseases
Stem Cell Transplantation
Therapeutics
Clinical Trials
Brain

Keywords

  • Huntington’s disease
  • Parkinson’s disease
  • Stem cells
  • amyotrophic lateral sclerosis
  • multi-system atrophy
  • multiple sclerosis
  • neuroprotection
  • stroke
  • traumatic brain injury

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Neal, E. G., Liska, M. G., Lippert, T., Lin, R., Gonzalez, M., Russo, E., ... Borlongan, C. V. (2018). An update on intracerebral stem cell grafts. Expert Review of Neurotherapeutics, 18(7), 557-572. https://doi.org/10.1080/14737175.2018.1491309

An update on intracerebral stem cell grafts. / Neal, Elliot G.; Liska, M. Grant; Lippert, Trenton; Lin, Roger; Gonzalez, Melissa; Russo, Eleonora; Xu, Kaya; Ji, Xunming; Vale Diaz, Fernando; Van Loveren, Harry; Borlongan, Cesario V.

In: Expert Review of Neurotherapeutics, Vol. 18, No. 7, 03.07.2018, p. 557-572.

Research output: Contribution to journalReview article

Neal, EG, Liska, MG, Lippert, T, Lin, R, Gonzalez, M, Russo, E, Xu, K, Ji, X, Vale Diaz, F, Van Loveren, H & Borlongan, CV 2018, 'An update on intracerebral stem cell grafts', Expert Review of Neurotherapeutics, vol. 18, no. 7, pp. 557-572. https://doi.org/10.1080/14737175.2018.1491309
Neal EG, Liska MG, Lippert T, Lin R, Gonzalez M, Russo E et al. An update on intracerebral stem cell grafts. Expert Review of Neurotherapeutics. 2018 Jul 3;18(7):557-572. https://doi.org/10.1080/14737175.2018.1491309
Neal, Elliot G. ; Liska, M. Grant ; Lippert, Trenton ; Lin, Roger ; Gonzalez, Melissa ; Russo, Eleonora ; Xu, Kaya ; Ji, Xunming ; Vale Diaz, Fernando ; Van Loveren, Harry ; Borlongan, Cesario V. / An update on intracerebral stem cell grafts. In: Expert Review of Neurotherapeutics. 2018 ; Vol. 18, No. 7. pp. 557-572.
@article{7917d6dfaa9b489a923123be7a79a32b,
title = "An update on intracerebral stem cell grafts",
abstract = "Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for clinically feasible stem cell-based treatments. Expert commentary: Intracerebral administration, compared to peripheral delivery, is more invasive and carries the risk of open brain surgery. However, direct cell implantation bypasses the blood–brain barrier and reduces the first-pass effect, effectively increasing the therapeutic cell deposition at its intended site of action. These benefits must be weighed with the risk of graft-versus-host immune response. Rigorous clinical trials are underway to assess the safety and efficacy of intracerebral transplants, and if successful will lead to widely available stem cell therapies for neurologic diseases in the coming years.",
keywords = "Huntington’s disease, Parkinson’s disease, Stem cells, amyotrophic lateral sclerosis, multi-system atrophy, multiple sclerosis, neuroprotection, stroke, traumatic brain injury",
author = "Neal, {Elliot G.} and Liska, {M. Grant} and Trenton Lippert and Roger Lin and Melissa Gonzalez and Eleonora Russo and Kaya Xu and Xunming Ji and {Vale Diaz}, Fernando and {Van Loveren}, Harry and Borlongan, {Cesario V.}",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/14737175.2018.1491309",
language = "English (US)",
volume = "18",
pages = "557--572",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - An update on intracerebral stem cell grafts

AU - Neal, Elliot G.

AU - Liska, M. Grant

AU - Lippert, Trenton

AU - Lin, Roger

AU - Gonzalez, Melissa

AU - Russo, Eleonora

AU - Xu, Kaya

AU - Ji, Xunming

AU - Vale Diaz, Fernando

AU - Van Loveren, Harry

AU - Borlongan, Cesario V.

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for clinically feasible stem cell-based treatments. Expert commentary: Intracerebral administration, compared to peripheral delivery, is more invasive and carries the risk of open brain surgery. However, direct cell implantation bypasses the blood–brain barrier and reduces the first-pass effect, effectively increasing the therapeutic cell deposition at its intended site of action. These benefits must be weighed with the risk of graft-versus-host immune response. Rigorous clinical trials are underway to assess the safety and efficacy of intracerebral transplants, and if successful will lead to widely available stem cell therapies for neurologic diseases in the coming years.

AB - Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for clinically feasible stem cell-based treatments. Expert commentary: Intracerebral administration, compared to peripheral delivery, is more invasive and carries the risk of open brain surgery. However, direct cell implantation bypasses the blood–brain barrier and reduces the first-pass effect, effectively increasing the therapeutic cell deposition at its intended site of action. These benefits must be weighed with the risk of graft-versus-host immune response. Rigorous clinical trials are underway to assess the safety and efficacy of intracerebral transplants, and if successful will lead to widely available stem cell therapies for neurologic diseases in the coming years.

KW - Huntington’s disease

KW - Parkinson’s disease

KW - Stem cells

KW - amyotrophic lateral sclerosis

KW - multi-system atrophy

KW - multiple sclerosis

KW - neuroprotection

KW - stroke

KW - traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85050204934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050204934&partnerID=8YFLogxK

U2 - 10.1080/14737175.2018.1491309

DO - 10.1080/14737175.2018.1491309

M3 - Review article

C2 - 29961357

AN - SCOPUS:85050204934

VL - 18

SP - 557

EP - 572

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 7

ER -